Amgen Shifts Its Focus From Products To Pipeline, But Stays In Comfort Zone
Executive Summary
Amgen Inc. is sticking to what it knows as it finally moves some of its mid-stage pipeline into later stages. Two of its most promising pipeline candidates, AMG 827 and AMG 785, are intended to be follow-on products to two of Amgen’s biggest franchises: Enbrel (etanercept) and Prolia/Xgeva (denosumab).
You may also be interested in...
Amgen Rethinks Ganitumab After Longshot Pancreatic Cancer Trial Fails
Hopes for IGF-1R inhibitor ganitumab had not been high due to past flops for others in the class. But research in extensive stage small-cell lung cancer and KRAS wild-type metastatic colorectal cancer goes on, at least for now.
A Maturing Amgen Focuses On Capital Allocation, Late-Stage Pipeline
Even as it reaffirms its big long-term bet on R&D, Amgen appeases investors with tweaks to its R&D organization and expansion of its share buyback program.
Radius Raises $91 Million, Moves Toward Public Listing
Just two years ago Radius Health Inc. had a straightforward partnering strategy for its osteoporosis drug, BA058. Now that a key partner has opted not to exercise its option on the compound, Radius has instead raised a massive new round of funding that allows the company to keep full ownership of the compound. In addition, the crafting of a creative exit strategy alongside the financing paves a path to liquidity for its shareholders.